Madrigal’s efforts for resmetirom will set tone for future launches of NASH therapies: GlobalData
In December 2022, the company successfully concluded raising a total of $309 million following positive topline data from the…
Sign in
Sign in
Recover your password.
A password will be e-mailed to you.
Browsing Tag
resmetirom
NASH market holds enormous untapped potential: GlobalData
Currently, Madrigal’s resmetirom (selective thyroid hormone receptor-β agonist; THR-Beta agonist) will most likely be the first…
Madrigal drug meets main goals in much-awaited NASH trial
The positive data sets the stage for the drug, resmetirom, to become the first treatment for NASH
Successive drug launches will drive growth of NASH market in seven major markets: GlobalData
The NASH market will undergo a very rapid growth, at a compound annual growth rate (CAGR) of 68.8 per cent from 2019 to 2029